FOLR2 and rheumatoid arthritis: Given the fact that macrophage PET imaging with FRβ has shown clinical feasibility in RA patients, future challenges will be to use folate PET tracers for detection of disease activity in early stage RA and monitoring/prediction of the therapy response of targeted synthetic or biological DMARDs in joints and other sides affected by systemic inflammation.